


U.S. & E.U. Differ on Filgotinib for RA

Canada & E.U. Approve Upadacitinib for RA

EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray

EU Approves Marketing for Ixekizumab in Adults with PsA

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?
Spanish Drugmaker Fears Disruption if EMA Moves from Britain
